NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: University of California, Los Angeles
Conditions: Interstitial Lung Disease, Idiopathic Interstitial Pneumonias, Drug-Induced Pneumonitis, Hypersensitivity Pneumonitis, Radiation Pneumonitis
Interventions: 68Ga-FAPi-46, Computed Tomography, Positron Emission Tomography, High Resolution Computed Tomography
Countries: United States
This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial lung disease. The study will include patients with interstitial lung disease who have or will initiate a new ILD medication OR will undergo tissue biopsy or surgery of the lung. The study will include 30 patients, the upper limit for PET imaging studies conducted under the Radioactive Drug Research Committee (RDRC) purview. Participants will be injected with up to 7 mCi of 68-GaFAPi and will undergo one PET/CT scan and one High Resolution CT of the lungs. The study is sponsored by Ahmanson Translational Theranostic Division at UCLA.
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion criteria * Patients with ILD confirmed by CT at time of staging * Patients who have initiated or will initiate a new ILD medication with 3 months of enrollment OR Patients who are scheduled to undergo tissue biopsy or surgery of the lung * Patients are ≥ 18 years old at the time of the radiotracer administration * Patient can provide written informed consent Exclusion criteria * Patient is pregnant or nursing * Patients with active infectious lung disease * Patients not expected to comply with the protocol requirements, not able to understand or follow trial procedures
- Los Angeles, California, United States